The preeclampsia diagnostics market is estimated to be valued at US$ 1587.53 Mn or in 2023 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Preeclampsia diagnostics include tests and tools used for diagnosing preeclampsia during pregnancy. Preeclampsia is a pregnancy complication characterized by high blood pressure and presence of protein in urine after 20 weeks of gestation. The diagnostics products available in the market include blood tests, ultrasound, and others. These diagnostics help identify women at high risk of developing preeclampsia and monitor their condition.
Market Dynamics:
Rising incidence of preeclampsia is expected to drive the growth of the market over the forecast period. According to the World Health Organization (WHO), preeclampsia complicates approximately 2–8% of all pregnancies worldwide. Moreover, early diagnosis and monitoring of high-risk pregnancies has significantly reduced the risk of mortality and morbidity due to preeclampsia. This is encouraging more women to opt for routine screening and diagnostic tests.
New product launches is another factor fueling the market growth. Key players are focusing on developing novel diagnostics with high accuracy and minimal invasiveness. For instance, in February 2022, DiabetOmics, Inc. launched Preevit, a blood test for early detection of preeclampsia between 10 to 20 weeks of gestation. Such innovations are expected to increase early detection and management of preeclampsia.
SWOT Analysis
Strength: Preeclampsia diagnostics market has strong growth potential due to the increasing incidence of preeclampsia among pregnant women. The development of novel diagnostic tests help in early detection and management of the condition. Moreover, rising awareness about the condition is prompting women to seek proper diagnostics.
Weakness: High costs associated with R&D of advanced diagnostic technologies can hamper the market growth. Additionally, lack of skilled professionals for operating complex diagnostic devices in low-income countries poses a challenge.
Opportunity: Growing healthcare investments by various governments worldwide presents an opportunity for market players. Furthermore, incorporation of AI and machine learning can help improve diagnostic accuracy and efficiency.
Threats: Stringent regulatory approvals delay the launch of new products. Limited medical reimbursements in developing nations also restrict the market growth.
Key Takeaways:
The global Preeclampsia Diagnostics Market size is expected to witness high growth, exhibiting CAGR of 11% over the forecast period, due to increasing adoption of advanced diagnostic tests. Rising incidence of preeclampsia and growth in healthcare expenditure are fueling the market growth.
Regional analysis: North America dominates the global market and is expected to continue its dominance over the forecast period. This is attributed to presence of advanced healthcare facilities and early adoption of innovative diagnostics. Asia Pacific exhibits the fastest growth due to growing healthcare awareness, improving research capabilities and increasing patient pool in countries like China and India.
Key players operating in the preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc. Strategic collaborations and new product launches are among the key strategies adopted by these players to gain a competitive edge in the market.
Read More,
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian